Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Danish biotechnology firm Genmab and BioNovion have entered into a co-development and commercialization agreement to evaluate a number of DuoBody product candidates targeting immune checkpoints.
Subscribe to our email newsletter
The deal will see the two companies supply panels of antibodies to develop bispecific antibody products using Genmab’s DuoBody platform technology.
If a product candidate is developed for clinical development by the two firms, development costs will be equally shared, while each party will retain a 50% share of the product rights.
Under the deal, if one of the companies decides not to move a therapeutic candidate forward, the other company is entitled to continue developing the product at predefined licensing terms.
Genmab chief executive officer Jan van de Winkel said: "We are pleased to expand our research collaboration with BioNovion into a full commercial agreement, and utilize our robust and versatile DuoBody technology to create unique differentiated cancer therapeutics in the promising field of immuno-oncology."
The deal also includes terms which allow the parties to opt out of joint development at key points in each product’s clinical development.
The company specializes in the creation and development of differentiated human antibody therapeutics for the treatment of cancer.